# Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

> **NCT05546476** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 187 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Loss of Appetite
- Fatigue
- Cachexia

## Interventions

- **DRUG:** ponsegromab
- **DRUG:** Placebo for ponsegromab

## Key facts

- **NCT ID:** NCT05546476
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-21
- **Primary completion:** 2024-03-13
- **Final completion:** 2025-04-23
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05546476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05546476, "Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05546476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*